Valo Health Inc. has disclosed sphingosine 1-phosphate receptor 1 (S1P1 receptor; EDG1) agonists reported to be useful for the treatment of multiple sclerosis, psoriasis, amyotrophic lateral sclerosis, systemic lupus erythematosus, ulcerative colitis, lymphopenia and Crohn’s disease.